Previous study indicated that the maintenance of gefitinib prevented the EMT process and inhibited cell migration in gefitinib-resistant NSCLC cells with MET-amplification (but without EMT phenotype) [48]. The gene discussed is MET; the disease is non-small cell lung carcinoma.